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Abstract
Objectives: To support the Bangladesh National Kala-azar Elimination Programme (NKEP), we investigated the feasibility of
using trained village volunteers for detecting post-kala-azar dermal leishmaniasis (PKDL) cases, using polymerase chain
reaction (PCR) for confirmation of diagnosis and treatment compliance by PKDL patients in Kanthal union of Trishal sub-
district, Mymensingh, Bangladesh.
Methods: In this cross-sectional study, Field Research Assistants (FRAs) conducted census in the study area, and the research
team trained village volunteers on how to look for PKDL suspects. The trained village volunteers (TVVs) visited each
household in the study area for PKDL suspects and referred the suspected PKDL cases to the study clinic. The suspected
cases underwent physical examinations by a qualified doctor and rK39 strip testing by the FRAs and, if positive, slit skin
examination (SSE), culture, and PCR of skin specimens and peripheral buffy coat were done. Those with evidence of
Leishmania donovani (LD) were referred for treatment. All the cases were followed for one year.
Results: The total population of the study area was 29,226 from 6,566 households. The TVVs referred 52 PKDL suspects.
Probable PKDL was diagnosed in 18 of the 52 PKDL suspect cases, and PKDL was confirmed in 9 of the 18 probable PKDL
cases. The prevalence of probable PKDL was 6.2 per 10,000 people in the study area. Thirteen PKDL suspects self-reported
from outside the study area, and probable and confirmed PKDL was diagnosed in 10 of the 13 suspects and in 5 of 10
probable PKDL cases respectively. All probable PKDL cases had hypopigmented macules. The median time for PKDL
development was 36 months (IQR, 24–48). Evidence of the LD parasite was documented by SSE and PCR in 3.6% and 64.3%
of the cases, respectively. PCR positivity was associated with gender and severity of disease. Those who were untreated had
an increased risk (odds ratio=3.33, 95%CI 1.29–8.59) of having persistent skin lesions compared to those who were treated.
Patients’ treatment-seeking behavior and treatment compliance were poor.
Conclusion: Improved detection of PKDL cases by TVVs is feasible and useful. The NKEP should promote PCR for the
diagnosis of PKDL and should find ways for improving treatment compliance by patients.
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Introduction
Post-kala-azar dermal leishmanisis (PKDL), is a skin disorder,
usually develops in 10–20% and about 60% of patients with
visceral leishmaniasis (VL)/kala-azar after treatment, respectively,
in the Indian subcontinent and Sudan [1]. It has also been
reported in individuals without prior history of VL and those
undergoing treatment for VL [1–6]. The protozoan parasite
Leishmania donovani (LD) is the only causative agent. Clinical
manifestations of PKDL are macular, maculo-papular, and
nodular rash in people who are otherwise well [1] and may be
confused with leprosy. Since PKDL is the only interepidemic
reservoir of anthroponotic VL, the existence of a few cases is
sufficient to trigger a new epidemic of VL in a given community
[1,4,7]. Thus, identification and treatment of PKDL is an essential
strategy in eliminating VL.
In 2005, Health Ministers of Bangladesh, India, and Nepal
signed a Memorandum of Understanding for the elimination of
VL from the Indian subcontinent by 2015 [8]. Active VL and
PKDL case detection and their proper management are two
important strategies of the elimination program [8]. Until now, no
definite method has been identified for active VL and PKDL case
detection but one proposed plan includes a house-to-house search
for cases by public-health workers. Such a method is expensive
and requires alternative strategies for VL and PKDL active case
detection [9].
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Brahmchari in 1922 [10]. Since then, nearly 90 years have passed
and no gold standard diagnostic method could be developed for
PKDL; diagnosis, thus, relies on clinical criteria [1–6]. PCR of slit
skin scraping specimens has demonstrated high sensitivity for
diagnosing PKDL in a laboratory-based study [11]. However, its
use in clinically-diagnosed PKDL patients is unknown. PCR
testing of peripheral blood buffy coat has been found to be a
highly-sensitive method for the diagnosis of VL [12,13], and
theoretically, it may help also confirm PKDL.
In Bangladesh, in the post-malaria-eradication era, the first
reports on PKDL were from hospital- based studies [14,15]. Until
now there has been limited information on the burden of PKDL in
the VL-endemic communities of Bangladesh [4]. Preliminary
results of an ongoing surveillance study of PKDL in Fulbaria,
Mymensingh, Bangladesh, showed that the burden of PKDL was
high and presents a challenge for the National Kala-azar Elimina-
tion Programme (NKEP) [4]. More information on the burden of
PKDL will help the NKEP to develop adequate national strategies
for controlling PKDL.
We therefore studied the feasibility of using trained village
volunteers (TVVs) for detecting suspected PKDL cases; estimated
the prevalence of PKDL in Kanthal Union, Trishal, a VL-
endemic area of Bangladesh; described the clinical features of
these patients; evaluated the contribution of PCR for the
confirmation of PKDL diagnosis in clinically-diagnosed PKDL
cases; and investigated the patients’ compliance to treatment.
Methods
Study area and population
We conducted a study in Kanthal union, Trishal sub-district
under Mymensingh district, Bangladesh. During January-March
2008, trained field research assistants performed a census in
Kanthal union. During the census, field research assistants assessed
household number and the number of people in each household.
They also asked and recorded whether any member within the
family suffered from kala-azar in the past and if any of them
currently had skin rash.
Trained village volunteers
After consulting the local community leaders and obtaining
their consent, one community volunteer was selected from each
ward. The research team trained the volunteers on what was
PKDL, how did a PKDL case looks like, and how to look for the
suspected PKDL case (see definitionbelow). A two-day training
was imported to the volunteers, and pictures of skin lesions from
PKDL patients from published literature and textbooks were used.
During April-May 2008, nine TVVs visited each household at
least once searching for suspected PKDL cases and, if found,
referred the case to the study clinic. Household members who had
a history of VL but were not present during the home-visits were
invited to visit to the study clinic for assessment. Additionally, the
study physician assessed patients with a history of VL and skin rash
who lived in villages outside the study area. Most of these patients
were directed to our study clinic from nearby public union health
posts where rK39 tests were not available.
Evaluation and procedures
The study physician examined the suspected PKDL cases and
requested an rK39 strip test (Kala-azar Detect
TM Rapid Test,
InBios International, Seattle, WA, USA) as needed. A trained field
research assistant performed the rK39 strip test as per the
manufacturer’s instructions. If the results were positive, the patients
were considered probable PKDL cases (see definition below) and
were requested to undergo slit skin scraping and blood collection. A
physician-microbiologist from the Bangabandhu Sheikh Mujib
Medical University (BSMMU) in Dhaka performed slit skin scraping
and collected skin specimens for staining, culture, and PCR test in
the study clinic. The study physician collected up to 5 mL of venous
blood in EDTA tubes and gently shook. After collection, the blood
and skin specimens were transported to the Parasitology Laboratory
of the International Centre for Diarrhoeal Disease Research,
Bangladesh (ICDDR,B) within 3–4 hours maintaining cold chain.
PCR tests were performed in the Parasitology Laboratory of
ICDDR,B on the following day, and the study physician was
informed about PCR results immediately after testing.
Treatment and follow-up
We referred all cases positive for the LD parasite or positive for
LD DNA by PCR to the Upazila Health Complex for treatment as
per the national guideline for kala-azar elimination [16]. After
referral, we followed up patients to find out whether they went to
the hospital for admission, and if admitted, whether they
completed full treatment courses. Further, we followed all the
probable PKDL patients after one year from the date of their
referral by household-visit and collected information on the status
of their skin rash. Patients who were rK39 test-negative were
referred to the Mymensingh Medical College Hospital for further
medical consultation.
Laboratory methods
Collection of slit skin scraping for staining, culture, and
PCR. The affected area of the skin was cleaned with 70% v/v
alcohol and allowed to dry completely. The edge of the lesion was
squeezed firmly between the finger and the thumb to drain the
area of blood. Using a sterile scalpel blade, a small incision was
made into the dermis; any blood was blotted away. The cut surface
was then scraped in an outward direction to obtain the tissue fluid
and cells for the following procedures:
Preparation of slides and process of staining
The materials were thinly spread on three-clean glass slides
using a circular motion working outwards to avoid damaging any
Author Summary
PKDL is a skin disorder which usually develops in 10–20%
and about 60% of patients with visceral leishmaniasis (VL)
after treatment respectively in the Indian subcontinent
and Sudan. However, cases among people without prior
VL have also been reported. Except skin lesion, PKDL
patients are healthy and usually do not feel sick. However,
persistence of a few PKDL cases is sufficient to initiate a
new epidemic of anthroponotic VL. Thus, identifying and
treating people with PKDL is a key strategy for the
elimination of kala-azar. Diagnosis of PKDL relies upon
clinical criteria and a serological test which is not specific
for PKDL. The use of the existing laboratory diagnostic
tools for confirmation of PKDL among PKDL suspects is
unknown. In the Indian subcontinent, PKDL is not self-
limited and needs to be treated with sodium stibogluco-
nate injections for 4–6 months. No data are available
relating to treatment compliance by patients, particularly
in Bangladesh. The results of the present study showed
that trained village volunteers were useful for identifying
PKDL suspects, and diagnostic confirmation improved with
the use of PCR. However, patients’ adherence to pre-
scribed treatment was poor.
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drops of absolute methanol for 2–3 minutes. The remaining slide
was heat- fixed by holding it, smear side up, over the flame of a
spirit lamp for a few seconds. After fixation, the slides were stored
and transported to the laboratory of BSMMU and stained with
modified Ziehl-Neelsen (Z-N) staining (using 5% sulphuric acid,
H2SO4). It was then examined under oil immersion lens using
100x oil immersion objectives to look for Mycobacterium leprae. The
methanol-fixed slides were stained with Giemsa stain and
examined for LD bodies.
Collection of slit skin scrapings for PCR
Collection of slit skin scraping specimens for PCR was done as
described previously [17], with little modification which included
collection of skin scrapings using a sterile cotton swab to maximize
the collection of tissue fluid and cells. After cutting the edge of the
lesion, a sterile cotton swab was used for absorbing the tissue fluid
and placed into an appendorf tube containing 500 mL of NET
buffer (150 Mm Nacl, 15 Mm Tris-HCl [pH-8.30]). The cotton
swab was kept in the tube for one hour before removal; and the
buffer solution was preserved at 220uC at the Parasitology
Laboratory of ICDDR,B until PCR was performed.
Collection of slit skin scrapings for culture
Slit skin scrapings were collected with sterile stainless steel wire
loops and inoculated in the Novy-MacNeal-Nicolle medium which
was transported to the Microbiology Laboratory of BSMMU, in a
air-conditioned car maintaining the temperature at 22uC and was
incubated at 22–24uC in the laboratory. Culture was examined
weekly and was kept up to four weeks before discarding as
negative.
Preparation of buffy coat. After arrival at the laboratory,
blood samples were centrifuged at 8000 rpm for 10 minutes at
room temperature, and 500 mL of buffy coat was collected from
the middle layer of the tube containing concentrated leukocytes.
The buffy coat was kept in a 1.5-mL sterile microcentrifuge tube
and preserved at 220uC for DNA extraction and PCR
amplification.
DNA extraction from buffy coat and skin slit. Buffy coat
DNA was extracted for PCR using QIAamp DNA blood mini kit
(Qiagen, Hilden, Germany, Cat. no. 51106) as per the
manufacturer’s instructions. The DNA was eluted in 0.2 mL of
AE buffer (supplied with the Qiagen kit). DNA was extracted from
the skin slit also following the manufacturer’s instructions, except
that the proteinase K digestion was carried out for 60 minutes at
50uC. The DNA was eluted in 0.2 mL of AE buffer (supplied with
the Qiagen kit). The purity of the DNA was satisfactory since a
ratio of OD at A260/A280 was within 1.7–1.9 for all DNA
samples. We used molecular-grade water instead of blood as an
extraction control for checking for carry-over contamination in
every run of DNA extraction and PCR amplification.
PCR methods. Leishmania-specific nested PCR (Ln-PCR) was
performed to detect LD DNA in peripheral buffy coat and skin
specimens using 2 mL of extracted DNA by the method described
previously [13], with primers targeting the parasite’s SSU-rRNA
region [12]. For the first PCR run, we used Kinetoplastida-specific
primers (R221 59-GGTTCCTTTCCTGATTTACG-39 and R332
59- GGCCGGTAAAGGCCGAATAG-39 ). For the second PCR,
1 mL of 1:50 dilution of the first PCR product was used as a
template in the presence of 0.15 mmol/L of the Leishmania-specific
primers R223 and R333.
Microscopy. Microscopy for LD bodies: At least two experts
examined the Giemsa stained slit skin slides for amastigotes and
also examined the wet film of culture for promastigotes.
Examination for M. leprae: At least two experts also looked for M.
leprae in the Z-N stained slit skin slides.
Definitions
Case definitions. A suspected PKDL patient was a person
from a kala-azar-endemic area with a past history of kala-azar and
a skin lesion. A probable PKDL case was a patient with suspected
PKDL who also had a positive rK39 test result. A confirmed
PKDL case included those probably PKDL cases who also had the
LD parasite identified by slit skin examination or culture, or had a
PCR test positive for LD DNA. All the confirmed PKDL cases
were referred to the Upazila Health Complex for treatment as per
the national guideline for kala-azar elimination [16]. However, all
analyses presented in this paper are based on clinically-defined
PKDL with positive rK39 dipstick test, i.e. probable PKDL cases.
Age-groups. The study population was divided into three
age-groups: ,15 years; 15–43 years; and $44 years.
Duration of onset of PKDL. Duration was defined in
months between the past treatment history of VL and the onset
of skin lesion as reported by the patient.
Grading of PKDL. Skin lesions were graded into three major
categories as described previously [1]. Briefly, grade I included
scattered maculopapular or nodular rash in the face with or
without some involvement in the upper chest or arm; grade II
included maculopapular or nodular rash mostly of the face and
extending to the chest, back, upper arms, and legs; and grade III
included maculopapular or nodular rash covering most parts of
the body, including hands and feet.
Progression of skin lesions. Based on case history given by
the patients, the study physician categorized progression of skin
lesions into rapid (conspicuous/obvious progression every month
from onset), gradual (clear, steady progression from onset but at
less detectable pace), and slow/stagnant (appearance, with little or
no progression throughout early months).
Treatment categories. Complete treatment was defined
when a patient completed the full treatment course of 20
consecutive days per month for consecutive six months with
sodium stibogluconate at a dose of 20 mg/kg/day and with a gap
of 10 days between courses. Termination of treatment before its
completion was defined as incomplete/partial treatment, and if a
patient refused treatment with sodium stibogluconate, it was
defined as refusal of treatment.
Cure of PKDL. Cure was defined as complete disappearance
of skin lesion(s) after treatment, as reported by the patient and
assessed by the trained Field Research Assistant.
Calculation of sample-size and statistical analysis
Assuming a PKDL prevalence of 0.04% (95% CI 0.03–0.05),
the required sample-size needed to search for PKDL cases was
25,098. A total population of 29,226 in the study area was
sufficient for our study. All data were computed using the EpiInfo
software (version 3.2.2.) and were analyzed using the SPSS
software (version 11.0) through descriptive and analytical methods.
Comparison between proportions was done by chi-square with
Fisher’s exact correction. Means were compared by ANOVA or
Kruskal-Wallis where applicable. We used Kaplan-Meier survival
curves to identify the median time for onset of PKDL after the
completion of VL treatment. All p values were two-tailed, and a p
value of #0.05 was considered significant.
Ethical consideration
The Ethical Review Committees of both ICDDR,B and
Tropical Disease Research/WHO approved the study. Written
informed consent was obtained from each study participant and
from parents/legal guardian for all child participants. Written
informed consent also was obtained from the head of each
household when performing the census.
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Prevalence of PKDL in study area
The census performed by the Field Research Assistants revealed
a total population of 29,226 people from 6,566 households: 11,298
people (38.7%) were aged #15 years, and the median family size
within each household was 5 (IQR 4–6). The Field Research
Assistants also listed a total of 235 individuals with a past history of
VL and 21 suspected PKDL patients based on the information
obtained during their visits to households at the beginning of the
study. However, the TVVs referred 52 suspected PKDL patients,
including the 21 cases, listed by the Field Research Assistants from
the study area. No cases from the study area were self- reported
but 13 patients were self-reported from villages outside the study
area. No new cases of suspected PKDL from the study area were
found in the following months after the initial survey by the TVVs.
Of the referred and self-reported suspected PKDL cases, 18 of
52 (34.6%) and 10 of 13 (76.9%) were respectively found to be
probable PKDL cases. The referred and self-reported probable
PKDL cases did not differ regarding age [mean years 6standard
error (SE), 24.163.7 for referred cases, 18.563.3 for self-reported
cases, p=0.33], sex (% of male patients, 55.6% for referred vs
40.0% self-reported, p=0.69), and duration of onset of PKDL
(mean years6SE, 46.065.1 for referred vs 36.0623.1 for self-
reported cases, p=0.29). PKDL was confirmed in 50% of the
patients from each group (9/18 for referred and 5/10 for self-
reported suspected PKDL patients). The calculated prevalence of
probable PKDL in the study area was 6.2 per 10,000 people,
slightly more common among the age-group of 15–43 years and
without any relation with gender [Table 1].
Characteristics of PKDL patients
We pooled all the 28 probable PKDL cases for further analysis.
The median age of the patients was 21.5 years (IQR, 10.7–29.0),
and the large majority (67.9%) was aged $15 years. All the
patients had previously been treated for VL with sodium
stibogluconate for 28 consecutive days, except one (3.6%) who
had interruption in treatment. The median duration of onset of
PKDL was 36 months (IQR, 24–48) (Fig. 1). The duration of onset
of PKDL was not related to gender (38.5765.9, n=14 for females
vs 46.7165.9, n=14 for males, p=0.34) but the younger group
developed PKDL significantly earlier compared to the older age-
group (26.6763.8 months, n=9, vs 50.2165.1 months, n=19,
p=0.006).
Hypopigmented macules were the most common skin lesions
and most frequently appeared first on the face (Table 2). In most
(94.4%) cases, the skin lesions progressed gradually and were
associated with itching in 25% of the cases. Eight of the 28 (29%)
cases, skin lesions were classified as grade I and the remaining 20
(71%) as grade II at the time of presentation to the study clinic.
The severity of the disease, as estimated by grading, showed no
association with sex: 11 of the 14 females (78.6%) and 9 of the 14
males (64.3%) had grade II PKDL, p=0.34. Similarly, the severity
of the disease had no association with age-group (78% vs 68%
grade II respectively in the younger and older age-groups,
p=0.48) nor the duration of onset of PKDL (r=0.03, p=0.9).
Laboratory findings
All the patients were negative for M. leprae (Table 3). All the 28
cultures were negative for Leishmania parasites. Slit skin
microscopy found LD bodies only in one of the 28 patients. Of
the 28 patients 12 (42.9%) were positive by slit skin scraping
specimen PCR and 14 (50%) by peripheral blood buffy coat PCR.
The PCR method was positive in 64% of the patients, defined by
any PCR test-positive (Table 3). The buffy coat PCR results were
positively associated with the severity of the disease: 65% (13/20)
of grade II PKDL patients were positive for peripheral buffy coat
PCR compared to 12.5% (1/8) of the PKDL patients with grade I
disease (p=0.012). However, skin specimen PCR results did not
show a similar relationship with PKDL grades: 45% (9/20) and
37% (3/8) respectively with grade II PKDL and grade I PKDL
were positive by skin specimen PCR (p=0.72). The female
patients had significantly more peripheral buffy coat PCR-positive
results compared to the male patients [10/14 (71%) for female vs.
4/14 (29%) for male patients, p=0.023]. The female patients were
also more likely to have a positive skin specimen by PCR (50%, 7/
14) compared to the male patients (36%, 5/14) but the difference
was not statistically significant (p=0.45).
Treatment and follow-up
Eighteen patients positive for the evidence of the LD parasite (1
by both LD body and LD DNA and 17 by LD DNA only) by any
laboratory method were referred to the sub-district hospital for
treatment. Of these patients, 7 completed treatment, 6 partially
completed treatment, and 5 refused treatment. The common
reasons for incomplete treatment or not to be treated were
concern about loss of daily wages, loss of school days, and
insolvency (Table 4). All the patients with complete treatment, half
of those with incomplete treatment, and none who refused
treatment were cured at follow-up. Compared to those with
complete treatment, the risk of not being cured with incomplete
treatment or treatment refusal was three times higher (relative risk
3.33, 95% CI 1.29–8.59, p=0.004). Ten of the 28 patients were
not referred for treatment due to lack of evidence of the LD
parasite in their skin or blood. At follow-up after one year, 8 of 10
patients had persistent skin lesions; skin lesions had deteriorated in
1 patient, and 1 was spontaneously cured.
Discussion
The major findings of the present study were: the TVVs were
useful for the active detection of PKDL case; the prevalence of
PKDL was high in the study area; PCR was useful for the
confirmation of PKDL diagnosis; and low treatment compliance
and current treatment-seeking behavior of PKDL patients present
Table 1. Distribution and prevalence of probable PKDL
patients by sex and age group in Kanthal.
Total number
of people in
the study area
Number of
probable PKDL
patients
Prevalence of
probable PKDL
per 10,000
people
Sex
Male 14999 10 6.7
a
Female 14227 08 5.6
Age group
,15 years old 10569 05 4.7
15–43 years old 13535 11 8.1
bc
$44 years old 5122 02 3.9
Total 29226 18 6.2
aP=0.72 compare to Female group;
bP=0.31 vs. ,15 years old and
cP=0.53 vs. $44 years old.
doi:10.1371/journal.pntd.0000832.t001
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in Bangladesh.
The Government of Bangladesh is committed to eliminate VL
by 2015, and active detection of VL and PKDL cases is one of the
main pillars of this elimination programme [8,16]. The active
Figure 1. Time for developing PKDL after completion of treatment for visceral leishmaniasis.
doi:10.1371/journal.pntd.0000832.g001
Table 2. Clinical information of probable PKDL patients,
n=28.
Indicators % (n)
First involvement of rash
Face 60.7 (17)
Arms 28.6 (8)
Other part of the body 10.7 (3)
Rash progression
Gradual 96.4 (27)
Slow/stagnant 3.6 (1)
Type of rashes
hypopigmented macules/patches/confluent plaques 100.0 (28)
hypopigmented papules 10.7 (3)
nodule 3.6 (1)
doi:10.1371/journal.pntd.0000832.t002
Table 3. Laboratory findings in 28 probable PKDL patients.
Laboratory Method Positive % (n/28)
Microscopy for M. Leprae 0 (0)
Culture for Leishmania promastigote 0 (0)
Microscopy of slit skin scraping specimens 3.6 (1)
PCR
Slit skin scraping specimens 42.9 (12)
Peripheral buffy coat 50.0 (14)
Any positive 64.3 (18)
doi:10.1371/journal.pntd.0000832.t003
Enhanced Case Detection of PKDL
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rural Bangladesh may not be possible due to lack of human
resources. We found that the TVVs were useful for finding
suspected PKDL cases. Thus, the TVVs should be used by the
NKEP for an annual active case search. We feel that it is sufficient
to conduct an annual search, particularly for PKDL, since no new
cases of suspected PKDL were found in our study after the initial
active case search by the TVVs.
The proportion of PKDL cases among the self-reported suspects
was higher (76.9%) compared to the referred PKDL cases (34.6%).
The majority of the self-reported cases were directed to our study
clinic from nearby public union health posts that lacked facilities
for rK39 testing. This suggests that many people are concerned
about signs and symptoms of possible PKDL but remain
undiagnosed due to lack of diagnostic facilities, particularly
rK39-based rapid tests, in the union health posts. The NKEP
should thus, strengthen the existing public union health posts in
the VL-endemic areas by equipping them with tools to diagnose
PKDL.
Clinical manifestations of the PKDL cases did not differ from
those reported in the literature [1–6,18]. We found that the
median duration of onset of PKDL was slightly longer compared
to that reported recently [4]. This difference might be explained
by the differences in the study design, and recall bias in our study
population also might contribute to this difference. Itching was
reported in 25% of the cases. This symptom among the PKDL
patients was also reported by others, and inflammatory reactions
in the dermis observed by Ismail et al might explain this symptom
[19].
The prevalence of PKDL in our study was 6.2 per 10,000
people which was lower than that found by a recent study in
another VL-endemic area of Bangladesh [3]. The limitation of our
study was that the TVVs looked for the suspected PKDL cases
based on the past history of VL and skin rash. Since PKDL may
develop in individuals without a past history of VL, it was possible
that the TVVs could not track all suspected PKDL cases.
However, we believe that this risk was minimal because the
percentage of PKDL without past history of VL was low (about
Table 4. Laboratory diagnosis, referral and treatment compliance of probable PKDL patients.
Patient
Age
(years) Sex
PKDL
Grade
Slit skin
examination
Culture
of skin
specimens
for LD
*PCR
Result
Referred for
treatment
Treatment
status (number
of injections)
Reason of
partial treat-
ment or not
treated
Status after
one year
T-085 26.00 Male 2 Negative Negative 2 Yes Partial (18) Loss of wages Not cured
T-013 30.00 Female 2 Negative Negative 3 Yes Complete (120) - Cured
T-073 7.00 Female 2 Negative Negative 3 Yes Complete (120) - Cured
T-034 34.33 Female 1 Negative Negative 2 Yes Complete (120) - Cured
T-035 25.00 Female 3 Negative Negative 3 Yes Complete (120) - Cured
T-015 7.00 Female 2 Negative Negative 1 Yes Partial (54) Insolvency Not cured
T-019 26.00 Male 2 Negative Negative 3 Yes Complete (120) - Cured
T-028 45.00 Male 2 Negative Negative 3 Yes Partial (59) Insolvency Not cured
T-084 13.00 Female 1 Negative Negative 3 Yes Complete (120) - Cured
T-040 22.00 Male 1 Negative Negative 2 Yes Partial (62) Insolvency Cured
T-041 17.00 Female 2 Negative Negative 2 Yes Partial (40) Loss of school days Cured
T-042 10.00 Female 2 Negative Negative 1 Yes Partial (40) Loss of school days Cured
T-057 7.00 Female 2 Negative Negative 1 Yes Complete (120) - Cured
T-022 70.00 Male 2 Negative Negative 0 No Not referred - Cured
T-072 25.00 Male 1 Negative Negative 0 No Not referred - Not cured
T-074 2.25 Male 2 Negative Negative 0 No Not referred - Not cured
T-087 20.00 Male 2 Negative Negative 0 No Not referred - Not cured
T-088 30.00 Female 1 Negative Negative 0 No Not referred - Not cured
T-120 13.00 Male 1 Negative Negative 0 No Not referred - Not cured
T-121 10.00 Male 2 Negative Negative 0 No Not referred - Not cured
T-123 25.00 Female 2 Negative Negative 0 No Not referred - Rash increased
T-124 2.50 Female 2 Negative Negative 1 Yes Not taken Does not feel sick Not cured
T-126 19.00 Male 1 Negative Negative 0 No Not referred - Not cured
T-141 21.00 Male 1 Negative Negative 0 No Not referred - Not cured
T-029 25.00 Male 2 Negative Negative 1 Yes Not taken Loss of wages Not cured
T-063 30.00 Female 2 Negative Negative 1 Yes Not taken Does not feel sick Not cured
T-086 38.00 Female 2 Negative Negative 3 Yes Not taken Does not feel sick Not cured
T-110 20.00 Male 2 Positive Negative 3 Yes Not taken Loss of wages Not cured
*0= Negative both by skin specimen PCR and peripheral blood buffy coat PCR, 1= positive by only peripheral buffy coat PCR, 2= positive only by skin specimen PCR,
3= Positive by both PCR.
doi:10.1371/journal.pntd.0000832.t004
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reported PKDL case from Kanthal union was presented to the
study clinic or the Upazila Health Complex in the months
following the study.
Slit skin examination and culture methods were not very much
useful for the diagnosis of PKDL since the LD parasite was found
in only one by slit skin examination, and all the 28 cases were
negative by culture method. Similar results were reported by
others [18]. PCR of skin specimens and peripheral blood buffy
coat was more useful for the detection of LD compared to slit skin
examination and culture. PCR helped confirm the diagnosis of
PKDL in additional 17 patients who were negative for LD by
conventional methods. Seven of the 17 patients who received
complete treatment were cured. Without this useful diagnostic
tool, these 7 patients would not be considered PKDL patients
because they were negative by SSE and culture and would
continue to serve as a reservoir of anthroponotic VL, thus
threatening the community’s health. In Bangladesh, many tertiary
hospitals are now equipped with PCR technology. Thus, the
NKEP should consider the use of PCR for the diagnosis of PKDL.
However, the feasibility and cost-effectiveness of such a diagnostic
algorithm may be a concern for the NKEP and needs to be
explored first.
We observed a significantly-positive relationship between
PKDL grade and PCR positivity, particularly with peripheral
blood buffy coat PCR. The circulation of the LD parasites in
peripheral blood increases with the severity of disease and
indirectly indicated that the origin of LD DNA in blood was skin.
So far, this is the first documentation of such a relationship
between PKDL grade and PCR method. It also supports an earlier
experiment that patients with PKDL may serve as a reservoir for
the transmission of the LD parasite which circulates in their blood
[20]. Although the severity of PKDL was equally distributed
among the males and females, the positive PCR results were more
common in the females, especially for peripheral buffy coat PCR.
We have no explanation for this phenomenon.
Ten of the 28 probable PKDL cases were not referred for
treatment because we failed to demonstrate LD or LD DNA
among them. At follow-up, only one had improvement in his skin
rashes, which occurred spontaneously. Our current diagnostic
capabilities limited our ability to determine whether these 10 cases
were false-positive probable PKDL cases or if they were false-
negative confirmed PKDL cases. The former explanation is less
likely to be true because PKDL is typically not self-limited in the
Indian subcontinent and less likely to be cured without treatment
[1–6]. All except one patient had persistent skin lesions after a one
year in this study. Thus, the development of more sensitive tests for
the diagnosis of PKDL is urgently needed and should be
encouraged by national and international researchers and funding
agencies.
The poor treatment-seeking behavior of and treatment
compliance by patients with PKDL patients present a challenge
for the NKEP. Only seven of the 18 cases (38.9%) completed
treatment after referral to the hospital. The reason behind not
being treated and partially treated was respectively feeling
otherwise healthy and concern about loss of daily wage or loss
of school day. Intensive motivation and some financial support
from the NKEP may improve this situation.
In conclusion, the prevalence of PKDL is high in a VL-endemic
area of Bangladesh. The use of TVVs feasible to actively detect
PKDL suspects, and in conjunction with PCR techniques, this
holds promise as an effective strategy for the NKEP to help meet
goals for the elimination of VL, if the ways for improving
treatment-seeking behavior and treatment compliance are found.
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